Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Ohr Pharmaceutical Inc. (OHRP-OTC: BB) |
|
|
While other drugs that have been tried in the area target one or the other symptom of the condition, none of the current drugs available on the market today, address the entire picture of cachexia, and adequately treat all the clinical symptoms because they do not address the root etiology. Our drug, OHR/AVR118 actually controls the bio-chemical cytokine storm and therefore mitigates many of the symptoms of cachexia, not just one or two. - Dr. Irach B. Taraporewala B.S., M.S., Ph.D. (Interview published February 11, 2011) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Ohr Pharmaceutical
Announces Positive Animal Studies for Novel Squalamine Eye Drop for
Wet-AMD Ohr Pharmaceutical Inc OHRP | 7/13/2011 8:15:12 AM
Studies
Confirm Ocular Safety and Therapeutic Concentrations in the Back of
the Eye Ohr Pharmaceutical (OTCBB: OHRP) today announced positive results from two critical animal studies on the recently announced Squalamine eye drop formulation for the treatment of wet-age related macular degeneration ("wet-AMD"). The data from the two animal studies indicate that the novel eye drop formulation is safe when applied to the eye, and furthermore it enters the tissues in the back of the eye in concentrations known to block choroidal neovascularization ("CNV").
In a separate drug bio-distribution study, a single eye drop was administered to the front of the eye in Dutch belted rabbits. At all evaluated timepoints, drug concentrations in the posterior sclera-choroid region behind the retina at the back of the eye far exceeded the tissue concentrations of Squalamine that are known to block the deleterious CNV process in wet-AMD. The study results also demonstrated that the drug was undetectable in the anterior chamber of the eye (aqueous humor), confirming that it does not penetrate through all the layers of the cornea or contact the lens. Topical treatment eliminates the major discomforts and serious complications of the current standard of care, Lucentis(R), which include endophthalmitis (severe vision threatening infection) and retinal detachment.
Thomas A. Ciulla M.D., retina specialist at The Midwest Eye Institute in Indianapolis, Indiana commented, "The retina community eagerly looks forward to a less frequent and less invasive treatment regimen. Topical treatment, either as monotherapy or as adjunctive therapy to decrease the frequency of visits and intravitreal injections, will represent a significant step in the right direction for treatment of exudative age-related macular degeneration."
About Wet Age Related Macular Degeneration Wet-AMD is a medical condition which usually affects older adults and generally results in a loss of vision. AMD occurs in "dry" and "wet" forms. Wet-AMD is the advanced form of macular degeneration that robs the elderly of their eyesight, and involves the formation of abnormal and leaky blood vessels in the back of the eye behind the retina, through a process known as choroidal neovascularization ("CNV"). The wet form accounts for approximately 15 percent of all AMD, yet is responsible for 90 percent of severe vision loss associated with AMD. According to the National Eye Institute (NEI), the prevalence of wet-AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed yearly in the U.S.
Contact: Ohr Pharmaceutical Inc. Sam Backenroth Vice President, Business Development 212-682-8452 Email Contact SOURCE: Ohr Pharmaceutical Inc.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.